Imaging test for predicting AL cardiac amyloidosis outcomes
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with AL cardiac amyloidosis based on a biopsy of your heart or another part of your body.
- If the biopsy was not from your heart, you also need certain heart test results: a blood test for NT-proBNP over 332 pg/mL, and a heart wall thickness over 12 mm on imaging.
- You must be receiving standard treatments for AL cardiac amyloidosis, like chemotherapy or supportive care.
- You cannot have an active infection or advanced cancer that limits your expected survival to less than 12 months.
- You cannot have severe memory problems, limited mobility, or other conditions that make it hard to complete imaging tests or follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study tests different heart scans to find heart amyloidosis, a condition where abnormal proteins build up in the heart, in people who have certain warning signs. The goal is to see which test works best to help diagnose it faster.
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.